Please try another search
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Timothy R. Pearson | 53 | 2014 | Independent Chairman of the Board |
Patricia S. Andrews | 62 | 2017 | Independent Director |
Scott T. Jackson | 56 | 2018 | Independent Director |
Scott Koenig | 69 | 2017 | Independent Director |
Harout Semerjian | 52 | 2021 | CEO, President & Director |
Daniel M. Junius | 71 | 2016 | Independent Director |
Rachel K. King | 64 | 2003 | Co-Founder & Director |
Mark A. Goldberg | 69 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review